Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Grace Therapeutics Inc GRCE

Healthcare Biotechnology
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company’s lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a... see more

Recent & Breaking News (NDAQ:GRCE)

Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2021

GlobeNewswire August 13, 2020

Acasti Pharma Submits Statistical Analysis Plan to FDA and Remains On Track to Report TRILOGY 2 Topline Data On or About August 31, 2020

GlobeNewswire July 31, 2020

Acasti Pharma Provides Fiscal 2020 Year-End Business Update

GlobeNewswire June 29, 2020

Acasti Pharma Receives FDA Response to TRILOGY 1 Briefing Package

GlobeNewswire June 19, 2020

Acasti Pharma Announces Submission of TRILOGY 1 Briefing Package to FDA

GlobeNewswire April 30, 2020

Acasti Pharma Awarded Notice of Allowance for Second Composition of Matter Patent in Canada

GlobeNewswire April 20, 2020

Acasti Pharma Submits FDA Meeting Request on Schedule, and FDA Meeting Expected in the Second Half of June

GlobeNewswire April 1, 2020

The Top Healthcare Bullboards: Jan - Mar 2020

Stockhouse Editorial March 23, 2020

Acasti Pharma Awarded Notice of Allowance for Additional Composition of Matter and Method of Use Patents in the United States and Mexico

GlobeNewswire March 11, 2020

Acasti Receives NASDAQ Notification Regarding Minimum Bid Requirements

GlobeNewswire February 28, 2020

Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2020

GlobeNewswire February 14, 2020

Acasti Pharma Schedules Third Quarter Fiscal 2020 and Business Update Conference Call

GlobeNewswire February 13, 2020

Acasti Pharma Provides Update on TRILOGY 1 and TRILOGY 2 Phase 3 Trials of CaPre

GlobeNewswire February 10, 2020

Acasti Pharma Reports Topline Results for TRILOGY 1 Phase 3 Trial of CaPre

GlobeNewswire January 13, 2020

IIROC Trading Resumption - ACST

Canada NewsWire December 24, 2019

Acasti Pharma Provides Update on Timing of Topline Results for TRILOGY 1 Phase 3 Trial of CaPre

GlobeNewswire December 23, 2019

IIROC Trading Halt - ACST

Canada NewsWire December 23, 2019

Acasti Pharma Reports Last Patient Visit in TRILOGY 1 Phase 3 Trial of CaPre for the Treatment of Severe Hypertriglyceridemia

GlobeNewswire November 26, 2019

Encode Ideas, L.P. Announces the Initiation of Research Coverage on Acasti Pharma, Inc.

Newsfile November 25, 2019

Acasti Pharma Releases Preliminary New Animal Data, and Gains Insights Into CaPre's Novel Mechanism of Action in Diabetes

GlobeNewswire November 18, 2019

Podcasts